Orthopedic Surgical Instrument Classification Rules
Summary
The Food and Drug Administration (FDA, the Agency, or we) is classifying orthopedic manual surgical instrumentation for use with non-fusion spinous process spacer devices into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of orthopedic manual surgical instrumentation for use with non-fusion spinous process spacer devices. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Compliance Requirements
- #1
Technical specifications regarding geometry of the instruments must be specified and validated to demonstrate that the instruments can safely position, place, or remove the implant.; The patient contacting components of the device must be demonstrated to be biocompatible.; Performance data must demonstrate that reprocessing of reusable devices that are provided non-sterile, or sterilization of devices provided sterile, is validated.; Labeling must include identification of implant(s) and instruments which have been validated for use together.; Labeling must include validated methods and instructions for reprocessing any reusable parts.; This device is subject to premarket notification requirements under section 510(k) of the FD&C Act (21 U.S.C. § 360(k)).
Market Impacts
Reclassification from potential class III to class II with special controls reduces regulatory burden and enhances market access for manufacturers of orthopedic manual surgical instrumentation for non-fusion spinous process spacer devices; Mandatory compliance with specific special controls including technical specifications validation, biocompatibility testing, reprocessing/sterilization validation, and specific labeling requirements; Increased demand for third-party testing and validation services required by the special controls (biocompatibility evaluation, reprocessing validation, sterilization validation); Premarket notification requirements under section 510(k) of FD&C Act remain applicable unless future exemption is granted, creating regulatory barrier to market entry
Validated Company Impacts
MERIT MEDICAL SYSTEMS INC
Merit Medical Systems primarily manufactures cardiovascular and interventional devices, not orthopedic surgical instrumentation. While they operate in the broader medical device sector and face FDA regulations, their specific product portfolio does not include the orthopedic manual surgical instrumentation targeted by this rule. The rule directly addresses two of the company's top regulatory risks - FDA regulatory clearance requirements and sterilization service provider dependency. The special controls for reprocessing/sterilization validation and premarket notification requirements align precisely with the company's identified risks of delays in product commercialization and sterilization service disruptions.
GLOBUS MEDICAL INC
Globus Medical Inc is a medical device manufacturer specializing in orthopedic products, including spinal implants and surgical instrumentation, which directly aligns with the rule's focus on orthopedic manual surgical instrumentation for non-fusion spinous process spacer devices. The company's regulatory compliance operations and product development activities would be directly affected by the special controls requirements including technical validation, biocompatibility testing, and labeling mandates. The company's only disclosed risk factor is data privacy compliance, which has no alignment with this FDA orthopedic device regulation focused on surgical instrumentation manufacturing requirements. The rule addresses technical specifications, biocompatibility, sterilization validation, and labeling requirements for medical device manufacturers, none of which relate to data privacy concerns.
STRYKER CORP
Stryker operates a significant Orthopaedics segment that includes spinal implants and surgical instrumentation, directly aligning with the rule's focus on orthopedic manual surgical instrumentation for non-fusion spinous process spacer devices. As a medical device manufacturer, the company would be subject to the technical specifications validation, biocompatibility testing, and labeling requirements specified in the rule. The rule specifically targets manufacturers of orthopedic surgical instrumentation, which does not align with the company's disclosed risk profile focused on financial, operational, and market competition risks. The company's single regulatory compliance risk appears to be general legal/regulatory exposure rather than specific medical device manufacturing compliance requirements.
ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet is a global medical technology leader that designs, manufactures, and markets orthopedic reconstructive products, directly aligning with the rule's focus on orthopedic manual surgical instrumentation for non-fusion spinous process spacer devices. The company's core business operations involve manufacturing orthopedic surgical instruments and implants, making them subject to the FDA's classification requirements, technical specifications validation, biocompatibility testing, and labeling mandates. The federal rule focuses entirely on medical device manufacturing compliance requirements, technical specifications, and regulatory classification for orthopedic surgical instruments. The company's only disclosed risk factor is cybersecurity threats, which has no connection to medical device manufacturing regulations, biocompatibility testing, or orthopedic instrumentation compliance.